Document is current
Any future updates will be listed below
-
Authors
Fang, Jiansong
Zhang, Pengyue
Wang, Quan
Chiang, Chien-Wei
Zhou, Yadi
Hou, Yuan
Xu, Jielin
Chen, Rui
Zhang, Bin
Lewis, Stephen J.
Leverenz, James B.
Pieper, Andrew A.
Li, Bingshan
Li, Lang
Cummings, Jeffrey
Cheng, Feixiong https://orcid.org/0000-0002-1736-2847
-
Funding
Funding for this research was provided by:
National Institute on Aging (R01AG066707, 3R01AG066707-01S1, R01AG069900, R35AG71476, R56AG063870, P30AG072959)
Foundation for the National Institutes of Health (U01AG073323)
National Institutes of Health (3R01AG066707-02S1)
- License Information
-
More Information
Article History
Received: 28 May 2021
Accepted: 16 December 2021
First Online: 10 January 2022
Declarations
:
: Not applicable
: Not applicable
: Dr. Cummings has provided consultation to Acadia, Actinogen, Alkahest, Alzheon, Annovis, Avanir, Axsome, Biogen, BioXcel, Cassava, Cerecin, Cerevel, Cortexyme, Cytox, EIP Pharma, Eisai, Foresight, GemVax, Genentech, Green Valley, Grifols, Karuna, Merck, Novo Nordisk, Otsuka, Resverlogix, Roche, Samumed, Samus, Signant Health, Suven, Third Rock, and United Neuroscience pharmaceutical and assessment companies. Dr. Cummings has stock options in ADAMAS, AnnovisBio, MedAvante, and BiOasis. Dr. Leverenz has received consulting fees from Vaxxinity, grant support from GE Healthcare and serves on a Data Safety Monitoring Board for Eisai. The other authors declare that they have no competing interests.
